Pharmaceutical Quality and Regulatory Oversight in India

The recent scandal involving cough syrup contamination has once again brought regulatory lacunae in India’s pharmaceutical industry to the forefront.

Background

Several child deaths in Madhya Pradesh and Rajasthan were reportedly linked to cough syrups containing diethylene glycol (DEG), a nephrotoxic substance.

Investigations revealed use of substandard excipients (like non‑pharmacopoeial grade propylene glycol) and violations of Schedule M norms.

Central and state agencies responded by suspending manufacturing licences and opening prosecutions.

Challenges in the Regulatory Framework

Fragmented oversight: overlapping jurisdictions of CDSCO, state drug controllers, police and legal agencies.

Weak preventive mechanisms: inspections are often reactive, not anticipatory.

Industry pressure: cost pressures may drive some firms toward cutting corners.

Lack of whistleblower protection and market surveillance infrastructure.

Way Forward: Towards a Zero‑Tolerance Approach

“Hawk‑like” continuous monitoring: surprise inspections, data analytics for anomaly detection.

Integration of enforcement: stronger coordination between drug regulators and police/intelligence agencies. Editorial in Indian Express argues regulation alone can’t bust organized spurious drug networks; policing capacity is needed.

Strengthening the pharmacovigilance network with citizen reporting, independent labs, and real‑time data.

Regulatory reforms: mandate “quality by design,” stricter audit trails, full traceability of raw materials.

Legal deterrents: fast‑track courts for drug liability, penal provisions for corporate and individual culpability.

Implications for Atmanirbhar Bharat

A self‑reliant India in pharma must rest on trust — drugs must be safe, affordable, and globally credible. Repeated lapses erode both domestic confidence and export potential.

Conclusion

A tragedy like child deaths is not just a policy failure but a moral one. To build a future in which “Made in India” also means “Safe in India,” we must move from reactive regulation to a systemic, zero‑tolerance regime.